29: Lipid-Lowering Drugs

CHAPTER 29 Lipid-Lowering Drugs

The transport of lipids in the blood requires their association with proteins. Fatty acids are transported in association with albumin, and triglycerides derived from dietary fat are transported in large macromolecular, cholesterol-containing particles known as lipoproteins. Cholesterol plays an essential role in human life as an important component of cell membranes and a precursor of steroid hormones and bile acids in addition to its role in triglyceride transport. Blood cholesterol levels previously thought to be normal are the cause of premature death, however, from coronary artery disease. Atherosclerosis remains the primary cause of premature death in the United States and in other industrialized countries. The major clinical sequelae of elevated lipoprotein levels, known as hyperlipidemias or hyperlipoproteinemias, are coronary artery disease, cerebrovascular disease, and peripheral vascular disease. The term hyperlipemia (which causes acute pancreatitis) is restricted to elevated plasma triglycerides without elevated cholesterol.

Because the deposition of cholesterol in arteries is a defining feature of atherosclerosis, strategies for its prevention and treatment include methods to reduce plasma cholesterol. Dentists need to understand lipid-lowering drugs as the overall dental patient population of the United States matures, and increasing numbers of patients take these drugs for prevention and therapy of atherosclerosis. Dentists also need to follow the development of the cholesterol synthesis inhibitors because of their implication in the stimulation of bone formation through inhibited isoprenoid synthesis leading to decreased osteoclast activity and increased osteoblast differentiation.23,28

Guidelines on patient cholesterol management are issued periodically by the Adult Treatment Panel of the National Cholesterol Education Program (NCEP).18 More recent guidelines have included recommendations for improved lifestyle changes, such as increasing exercise and decreasing consumption of saturated fat and cholesterol, which improve cholesterol levels in some patients without drug therapy.

CHOLESTEROL AND ATHEROSCLEROSIS

Atherosclerosis is caused by development of fatty streaks and plaques in large and medium-sized arteries, especially the aorta, coronary arteries, carotid arteries, renal arteries, and arteries of the legs. Plaques develop in the intimal wall of the vessels after deposition of cholesteryl esters derived from certain lipoproteins. The particular clinical manifestation of atherosclerosis depends on the degree to which the lesions have progressed in a particular part of the vasculature. The presence of atheromatous lesions can have several effects on the circulation to a prescribed area: (1) blood flow may be obstructed by the plaques themselves or by associated thrombi, (2) vascular reactivity and control of blood flow may be lost, and (3) vessels may become weakened and subject to rupture. Observations of initial lesions in young children have shown that this disease begins at an early age and progresses gradually, with clinical symptoms generally appearing much later in life.35,43

Foam cells are a primary characteristic of atheromatous plaques. These cells arise from macrophages that invade the injured arterial endothelium and accumulate large pools of cholesteryl esters from nearby trapped lipoproteins. As with all other cells, macrophages possess a mechanism for converting free cholesterol to cholesteryl esters as a protective mechanism to avoid excessive accumulation of free cholesterol in their membranes. Macrophages also possess scavenger receptors in their plasma membranes that bind chemically modified lipoproteins that arise from free radical–mediated oxidation or glycosylation because of poorly controlled diabetes.

The accumulation of foam cells results in a fatty streak visible to the naked eye. Particularly in vascular areas subject to high mechanical shear stresses and turbulent flow, microscopic tearing and disruption of the local endothelium may expose the underlying tissue, resulting in accelerated lipoprotein accumulation, platelet aggregation, and deposition of fibrin. Eventually, an atherosclerotic plaque forms with a thick fibrous cap covering a necrotic center composed of cellular debris and cholesteryl ester deposits.

Lipoprotein Metabolism

Classification of plasma lipoproteins is based on the density of the complexes, with a lower density indicating higher lipid content (Table 29-1). Chylomicrons are the largest particles and possess the greatest proportion of lipid. The other lipoproteins are very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and lipoprotein(a). Two separate lipoprotein-producing systems or metabolic pathways are responsible for the transport of lipids (Figure 29-1): the exogenous pathway, producing chylomicrons in the intestinal mucosa primarily from dietary fat, and the endogenous pathway, producing VLDL in the liver with triglycerides from hepatic metabolism of dietary carbohydrates.

A crucial factor in the understanding of physiologic and pathophysiologic aspects of lipoprotein metabolism is the role played by specific apoproteins, the proteins associated with lipoprotein particles. Chylomicrons serve to transport dietary lipids to the sites of use and storage. The major protein component of chylomicrons is apoprotein B48, which initially plays an entirely structural role in formation and transport. It forms the amphipathic coating of the particle along with unesterified cholesterol and phospholipid, which surrounds the hydrophobic core containing triglycerides and cholesteryl esters and allows the particle to remain suspended in an aqueous environment. On reaching the capillary endothelium of muscle and adipose tissue, the chylomicron triglycerides are rapidly degraded to fatty acids, glycerol, and monoglycerides by the enzyme lipoprotein lipase.

Apoprotein CII serves as a stimulus for endothelial lipase activity. The remaining chylomicron remnants, depleted of triglycerides and CII but relatively enriched in cholesterol and apoproteins B48 and E, are released back into the circulation. The exogenous pathway terminates in the liver, where the chylomicron remnants are actively taken up by hepatocytes. Apoproteins B48 and E help trigger this receptor-mediated endocytosis. Within the liver, the remnants are digested, releasing the remaining lipids for further metabolism (Figure 29-2).

The hepatic synthesis and release of VLDL particles initiates the endogenous pathway of lipid transport. VLDL is primarily triglyceride and is subject to attack by lipoprotein lipase on activation by apoprotein CII. The resulting IDL particle, greatly reduced in triglyceride content, has two possible fates: (1) a few particles are released and undergo receptor-mediated endocytosis by the liver and lysosomal degradation, or (2) most particles continue further removal of triglyceride and all apoproteins other than B100 to yield LDL. The cholesterol content of LDL is 50% to 60% by weight and normally accounts for 75% of the total plasma cholesterol. Particles of LDL are subject to apoprotein B100–dependent, LDL receptor–mediated endocytosis by various tissues, most importantly the liver. Excess IDL and LDL, through scavenger uptake by intimal macrophages, account for the cholesterol accumulation in atheromatous lesions. There is no evidence that chylomicrons are involved in this disease process.

The synthesis of cholesterol, regulated by the initial enzyme of the pathway (3-hydroxy-3-methylglutaryl–coenzyme A [HMG-CoA] reductase), is an energetically expensive process because every carbon atom of cholesterol is derived from acetylcoenzyme A, so the maintenance of total body cholesterol is a priority. This is exemplified further by the fact that there is no mechanism in the human body for removal of cholesterol other than conversion to bile acids and fecal excretion. Cholesterol is conserved through enterohepatic cycling and reverse cholesterol transport, processes that play important roles in energy conservation and sites of action for lipid-lowering drugs.

Enterohepatic cycling includes the following processes36: (1) synthesis of cholesterol and conversion to bile acids by the liver, (2) secretion of biliary cholesterol and bile acids into the small intestine, (3) absorption of bile acids from the terminal ileum, and (4) transfer through the portal system and reuptake by the liver. Reverse cholesterol transport is the process by which HDL synthesized by the liver and intestine takes up cholesterol from peripheral cells and transports it back to the liver. HDL cholesterol is sometimes referred to as the “good” cholesterol because it represents the amount of cholesterol being removed from most of the body and because higher levels of HDL cholesterol are associated with decreased risk of atherosclerosis. HDL also assists in the removal of triglycerides from the bloodstream by delivering to chylomicrons and VLDL the C and E apoproteins necessary for their processing.

Role of Lipoproteins in Atherosclerosis

The presence of cholesterol as an integral component of arterial plaques has been known for decades, and many studies have been done to determine whether abnormal concentrations of cholesterol are involved in the origin or progress of plaque formation. These studies have shown that plasma cholesterol concentrations are higher in patients with coronary artery disease than in normal patients, and that the relationship between serum cholesterol concentration and risk of premature death from coronary artery disease is continuous and graded.38,42 More recent studies of cholesterol reduction therapy in patients with hyperlipidemia have shown that reduction of plasma cholesterol can cause regression of plaque formation and decrease the mortality rate from atherosclerosis.18,44

An increase in plasma LDL may be caused either by overproduction of its VLDL precursor or, more commonly, by retarded clearance of LDL from the blood. The plasma half-life of LDL is much longer than the half-lives of VLDL and IDL. Although LDL receptor–dependent uptake predominates normally, only the alternative phagocytic pathway is available in patients with severe familial hypercholesterolemia, who congenitally lack functional LDL receptors.7 LDL contains most cholesterol in the plasma, and it is the lipoprotein group most directly associated with coronary heart disease.27,41 High plasma concentrations of HDL are inversely related to the risk of coronary heart disease.10,41

Hyperlipidemia may be primary (i.e., genetic in origin) or result from dietary factors; disease states such as diabetes mellitus, hypothyroidism, or uremia; drugs such as alcohol, oral contraceptives, or glucocorticoids; or a combination of causes. A summary of various types of primary hyperlipidemias is provided in Table 29-2.

Risk Factors in Atherosclerosis

In addition to high plasma cholesterol, several risk factors have been identified with an increased incidence of atherosclerosis, including hypertension, cigarette smoking, sedentary habits, obesity, diabetes mellitus, hypothyroidism, male gender, and a family history of atherosclerosis or diabetes. As shown in Table 29-2, the clinical manifestations of genetic or familial hyperlipoproteinemias are severe. The lipid-lowering agents discussed in this chapter have proved quite useful in treating many of these disorders and even in reversing the progression of atherosclerosis in patients without specific metabolic defects in lipid metabolism.

THERAPEUTIC AGENTS

Therapy with drugs that reduce plasma cholesterol is used to delay or reverse the progression of atherosclerosis and decrease the mortality and morbidity rates from the associated clinical manifestations of this disease. Strong evidence supports the idea that correction or lowering of plasma lipid concentrations is beneficial in many instances.18,41 These drugs are helpful in treating many familial hyperlipidemias, and they are recommended for use in patients with hyperlipidemias of secondary etiology that cannot be corrected by other means. Lipid-lowering drugs are most frequently administered to patients with a history of ischemic heart disease in an attempt to avoid future fatal episodes of myocardial infarction.

The goal of therapy is to reduce lipid levels as much as possible without producing metabolic derangements or adverse drug effects.38,42 Altering the diet is generally the initial therapeutic measure, along with correcting any disease state or condition contributing to hyperlipidemia. If nonpharmacologic therapy is insufficient, drug administration should be considered depending on determinants such as age, gender, presence of ischemic vascular disease, and coexistence of other risk factors. Even when pharmacologic antihyperlipidemic treatment is instituted, however, nonpharmacologic management, including reduction of dietary cholesterol and saturated fatty acids, weight reduction, exercise, and smoking cessation, remains the cornerstone of therapy.

The following hypolipidemic agents are considered in this chapter: (1) derivatives of fibric acid, including clofibrate and gemfibrozil; (2) nicotinic acid; (3) the bile acid sequestrants cholestyramine and colestipol; (4) inhibitors of HMG-CoA reductase; (5) cholesterol absorption inhibitors; and (6) other agents. The effects of the major drugs on the various classes of lipoprotein are listed in Table 29-3.

The choice of a drug depends on the lipoprotein profile of the patient, the efficacy of the drug in treating the abnormality, and the ability of the patient to tolerate the agent. Drug therapy to reduce plasma LDL concentrations often begins with an HMG-CoA reductase inhibitor, a bile acid sequestrant, or a combinatio/>

Jan 5, 2015 | Posted by in General Dentistry | Comments Off on 29: Lipid-Lowering Drugs
Premium Wordpress Themes by UFO Themes